Drug Profile
GS 9005
Alternative Names: GS 224338; GS 4338; GS GS '4883Latest Information Update: 01 Nov 2004
Price :
$50
*
At a glance
- Originator Gilead Sciences
- Class Antivirals
- Mechanism of Action Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 23 Oct 2004 Discontinued - Phase-I/II for HIV infections treatment in USA (unspecified route)
- 13 Jul 2004 Phase-I/II clinical trials in HIV infections treatment in USA (unspecified route)
- 14 Jan 2004 Gilead has filed an IND with the FDA in the US for HIV infections treatment